$74.4MSeries C, 11 February 2026
Accelerates US commercial expansion of NEUROMARK.
- Amount
- $74.4M
- Stage
- Series C
- Announced
- 11 February 2026
- Lead
- MVM Partners
- Other investors
- Sofinnova Partners, EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners, Enterprise Ireland
- Use of funds
- Accelerates US commercial expansion of NEUROMARK.
- Checked
- Announced by the company
- Sources
- Neurent Medical raises €62.5M Series C to expand NEUROMARK commercially biospace.com
Neurent Medical raises €62.5M Series C to expand NEUROMARK commercially pulse2.com